在耐多药 HIV 患者中使用来那卡韦的病例报告：亚洲首例

IF 2.6 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Yonsei Medical Journal Pub Date : 2024-10-01 DOI:10.3349/ymj.2023.0540

Yongseop Lee, Ki Hyun Lee, Jung Ah Lee, Sang Min Ahn, Min Han, Jun Yong Choi

{"title":"在耐多药 HIV 患者中使用来那卡韦的病例报告：亚洲首例","authors":"Yongseop Lee, Ki Hyun Lee, Jung Ah Lee, Sang Min Ahn, Min Han, Jun Yong Choi","doi":"10.3349/ymj.2023.0540","DOIUrl":null,"url":null,"abstract":"Lenacapavir is a novel, first-in-class, capsid inhibitor, which has been approved as an adjunctive therapy for multidrug-resistant human immunodeficiency virus (HIV)-1 virus in combination with optimized background regimen (OBR). Lenacapavir has demonstrated a significant decrease in viral load and high rate of virologic suppression in patients with multidrug-resistant HIV-1 infection with limited treatment options. Here, we report a case of 43-year-old male who was diagnosed with HIV-1 infection in 2005 but failed to achieve viral suppression due to multiclass resistance. After lenacapavir use with OBR, viral suppression was achieved, and recovery of CD4+ T-cell count was observed for 8 months. This case report shows the first lenacapavir experience in Asia in a heavily treatment-experienced HIV patient with limited treatment options.","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"65 10","pages":"619-622"},"PeriodicalIF":2.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427126/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia.\",\"authors\":\"Yongseop Lee, Ki Hyun Lee, Jung Ah Lee, Sang Min Ahn, Min Han, Jun Yong Choi\",\"doi\":\"10.3349/ymj.2023.0540\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lenacapavir is a novel, first-in-class, capsid inhibitor, which has been approved as an adjunctive therapy for multidrug-resistant human immunodeficiency virus (HIV)-1 virus in combination with optimized background regimen (OBR). Lenacapavir has demonstrated a significant decrease in viral load and high rate of virologic suppression in patients with multidrug-resistant HIV-1 infection with limited treatment options. Here, we report a case of 43-year-old male who was diagnosed with HIV-1 infection in 2005 but failed to achieve viral suppression due to multiclass resistance. After lenacapavir use with OBR, viral suppression was achieved, and recovery of CD4+ T-cell count was observed for 8 months. This case report shows the first lenacapavir experience in Asia in a heavily treatment-experienced HIV patient with limited treatment options.\",\"PeriodicalId\":23765,\"journal\":{\"name\":\"Yonsei Medical Journal\",\"volume\":\"65 10\",\"pages\":\"619-622\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427126/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Yonsei Medical Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3349/ymj.2023.0540\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Yonsei Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3349/ymj.2023.0540","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

来那卡帕韦是一种新型、首创的囊膜抑制剂，已被批准与优化背景疗法（OBR）联合作为治疗耐多药人类免疫缺陷病毒（HIV）-1 病毒的辅助疗法。在治疗方案有限的耐多药 HIV-1 病毒感染患者中，来那卡帕韦能显著降低病毒载量并提高病毒学抑制率。在此，我们报告了一例43岁的男性患者，他于2005年被诊断为HIV-1感染，但因多药耐药而未能实现病毒抑制。在使用来那卡韦联合 OBR 治疗后，病毒得到了抑制，CD4+ T 细胞计数恢复了 8 个月。本病例报告显示了来那卡韦在亚洲首次用于治疗治疗方案有限、治疗经验丰富的艾滋病患者的经验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia.

Lenacapavir is a novel, first-in-class, capsid inhibitor, which has been approved as an adjunctive therapy for multidrug-resistant human immunodeficiency virus (HIV)-1 virus in combination with optimized background regimen (OBR). Lenacapavir has demonstrated a significant decrease in viral load and high rate of virologic suppression in patients with multidrug-resistant HIV-1 infection with limited treatment options. Here, we report a case of 43-year-old male who was diagnosed with HIV-1 infection in 2005 but failed to achieve viral suppression due to multiclass resistance. After lenacapavir use with OBR, viral suppression was achieved, and recovery of CD4⁺ T-cell count was observed for 8 months. This case report shows the first lenacapavir experience in Asia in a heavily treatment-experienced HIV patient with limited treatment options.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Yonsei Medical Journal 医学-医学：内科

CiteScore

4.50

自引率

0.00%

发文量

167

审稿时长

3 months

期刊介绍： The goal of the Yonsei Medical Journal (YMJ) is to publish high quality manuscripts dedicated to clinical or basic research. Any authors affiliated with an accredited biomedical institution may submit manuscripts of original articles, review articles, case reports, brief communications, and letters to the Editor.